Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
CAMBRIDGE, Mass., Nov. 28, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference, being held on November 29-30 in New York City.
| 28th Annual Piper Jaffray Healthcare Conference | ||
| Date: | Wednesday, November 30 | |
| Time: | 1:00 pm Eastern Time | |
| Location: | The Lotte New York Palace Hotel, Holmes I Room | |
| Webcast: | http://edge.media-server.com/m/p/cfdngzft | |
About CoLucid Pharmaceuticals, Inc.
CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
